Daniel Peeper Lab
@peeperlab.bsky.social
Cancer researcher @NKI_nl and @oncodeinstitute, Cofounder of Flindr Tx; developing rational cancer & immune cell combination treatments using functional genomics
Reposted by Daniel Peeper Lab
In a new Nature Genetics paper our researchers identified a synthetic lethal interaction in 50% of cancers. Tumors lacking CDS1 depend entirely on CDS2. Blocking CDS2 kills cancer cells while sparing healthy tissue ➡️ www.nki.nl/news-events/...
July 7, 2025 at 9:29 AM
In a new Nature Genetics paper our researchers identified a synthetic lethal interaction in 50% of cancers. Tumors lacking CDS1 depend entirely on CDS2. Blocking CDS2 kills cancer cells while sparing healthy tissue ➡️ www.nki.nl/news-events/...
The SMR 2025 Annual Congress (Amsterdam Oct 25-28) covers basic, preclinical & translational melanoma research of international top investigators. It is a very enjoyable conference with top faculty and now improved with ample opportunity for young investigators to network. Join us! smrcongress.org
Society Melanoma Research Congress
smrcongress.org
July 4, 2025 at 12:23 PM
The SMR 2025 Annual Congress (Amsterdam Oct 25-28) covers basic, preclinical & translational melanoma research of international top investigators. It is a very enjoyable conference with top faculty and now improved with ample opportunity for young investigators to network. Join us! smrcongress.org
Major congratulations to my PhD student Tim Arnoldus @nkinl.bsky.social @oncodeinstitute.bsky.social on publishing his exciting discovery today in Nature Genetics! 🎉
By computational mining Tim found a synthetic lethal target that may impact future treatment of half of all cancers.👏
t.co/cQdeYQinsX
By computational mining Tim found a synthetic lethal target that may impact future treatment of half of all cancers.👏
t.co/cQdeYQinsX
https://www.nature.com/articles/s41588-025-02221-2
t.co
July 4, 2025 at 9:48 AM
Major congratulations to my PhD student Tim Arnoldus @nkinl.bsky.social @oncodeinstitute.bsky.social on publishing his exciting discovery today in Nature Genetics! 🎉
By computational mining Tim found a synthetic lethal target that may impact future treatment of half of all cancers.👏
t.co/cQdeYQinsX
By computational mining Tim found a synthetic lethal target that may impact future treatment of half of all cancers.👏
t.co/cQdeYQinsX
Congrats to Sofía Ibáñez Molero @NKI_nl and
@oncodeinstitute for excellently defending her PhD thesis, on functional interactions between cancer and the immune system, with several interesting papers already published and under review. Great work Sofía and best of luck with your postdoc!
@oncodeinstitute for excellently defending her PhD thesis, on functional interactions between cancer and the immune system, with several interesting papers already published and under review. Great work Sofía and best of luck with your postdoc!
January 24, 2025 at 10:56 AM
Congrats to Sofía Ibáñez Molero @NKI_nl and
@oncodeinstitute for excellently defending her PhD thesis, on functional interactions between cancer and the immune system, with several interesting papers already published and under review. Great work Sofía and best of luck with your postdoc!
@oncodeinstitute for excellently defending her PhD thesis, on functional interactions between cancer and the immune system, with several interesting papers already published and under review. Great work Sofía and best of luck with your postdoc!
📢 Applications for the NKI PhD program now open till Feb 28. Several exciting positions available, including one in my lab on discovering new biology and therapeutic opportunities of a population of enriched tumor-reactive T cells we recently identified.
www.nki.nl/careers-stud...
www.nki.nl/careers-stud...
NKI PhD program 2025 | Cancer Biology | Netherlands Cancer Institute
We are looking for outstanding candidates who want to become our new generation of ambitious PhD students, and join our lively international research community.
www.nki.nl
January 14, 2025 at 11:39 AM
📢 Applications for the NKI PhD program now open till Feb 28. Several exciting positions available, including one in my lab on discovering new biology and therapeutic opportunities of a population of enriched tumor-reactive T cells we recently identified.
www.nki.nl/careers-stud...
www.nki.nl/careers-stud...
Reposted by Daniel Peeper Lab
More knowledge about immunotherapy, advanced diagnostics, and reducing overtreatment. Thanks to financial support from KWF Dutch Cancer Society, 13 research teams from the Netherlands Cancer Institute are launching new projects ➡️ www.nki.nl/news-events/...
December 13, 2024 at 1:59 PM
More knowledge about immunotherapy, advanced diagnostics, and reducing overtreatment. Thanks to financial support from KWF Dutch Cancer Society, 13 research teams from the Netherlands Cancer Institute are launching new projects ➡️ www.nki.nl/news-events/...
Reposted by Daniel Peeper Lab
📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq
November 29, 2024 at 8:36 AM
📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq
My first post here: Congrats to David Vredevoogd from my lab @NKI_nl
@oncodeinstitute + collaborators for reporting on TMED, a new regulator of both immune checkpoints PD-1 and CTLA-4, which is amenable to therapeutic intervention. Read the paper here jitc.bmj.com/content/12/1...
@oncodeinstitute + collaborators for reporting on TMED, a new regulator of both immune checkpoints PD-1 and CTLA-4, which is amenable to therapeutic intervention. Read the paper here jitc.bmj.com/content/12/1...
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Background Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression on CD8 T ...
jitc.bmj.com
November 17, 2024 at 8:21 PM
My first post here: Congrats to David Vredevoogd from my lab @NKI_nl
@oncodeinstitute + collaborators for reporting on TMED, a new regulator of both immune checkpoints PD-1 and CTLA-4, which is amenable to therapeutic intervention. Read the paper here jitc.bmj.com/content/12/1...
@oncodeinstitute + collaborators for reporting on TMED, a new regulator of both immune checkpoints PD-1 and CTLA-4, which is amenable to therapeutic intervention. Read the paper here jitc.bmj.com/content/12/1...